| answer text |
<p>Nabiximols (Sativex) is licensed in the United Kingdom for the treatment of moderate
to severe spasticity in multiple sclerosis. The National Institute of Health and Care
Excellence (NICE) did not recommended nabiximols in its 2014 clinical guidelines as
it is not a cost-effective treatment.</p><p> </p><p>NICE develops authoritative, evidence-based
guidance on best practice for the National Health Service. NICE operates with a high
degree of independence from the Government and is responsible for the recommendations
that it makes to the NHS. Its guidance is based on a thorough assessment of the available
evidence and is developed through engagement with stakeholders.</p><p> </p><p>However,
where there is an absence of final guidance recommendations from NICE, decisions on
the funding of a licensed treatment on the NHS are taken by the relevant clinician
and commissioner (such as NHS England or individual clinical commissioning groups)
based on the individual needs of the patient.</p>
|
|
